Lixte appoints two new independent directors; CMO resigns effective July 31

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Board adds Jason Sawyer and Dr. Michael Holloway as independent directors, designated by Series B Preferred Stock holders.
Dr. Stephen Forman and Dr. Yun Yen resign from Board, will serve on Scientific Advisory Committee.
Mr. Sawyer named Chairman of Compensation Committee and member of Audit Committee.
Chief Medical Officer Dr. Jan Schellens resigns effective July 31, 2025; consulting agreement terminated.
Resignations not due to any disagreement with company operations, policies, or practices.

item 5.02

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.